Sex: U
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Interchange of vaccine products, Suspected COVID-19
Clinical narrative: Suspected COVID-19 infection; Interchange of vaccine products; This spontaneous case was reported by a physician and describes the occurrence of SUSPECTED COVID-19 (Suspected COVID-19 infection) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for Prophylactic vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) for Prophylactic vaccination.    Concurrent medical conditions included Drug allergy (Drug not specified).   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. and first dose of COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) (unknown route) 1 dosage form. On an unknown date, the patient experienced SUSPECTED COVID-19 (Suspected COVID-19 infection) (seriousness criterion medically significant) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) (oral) from 17-May-2022 to 22-May-2022 for COVID-19 treatment, at a dose of Unknown. At the time of the report, SUSPECTED COVID-19 (Suspected COVID-19 infection) was resolving and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  The patient received two doses (dose number 1 and 2) (booster) of Moderna. On an unspecified date, the patient experienced COVID- 19 (dose number in series 2). On 29-May-2022, the patient experienced rebound COVID-19 infection (suspected COVID-l9 infection) five days after completion of Paxlovid (batch number, form of admin was not reported and expiry: unknown) (dose number in series 2), The patient was recovering from rebound COVID-19 infection. This report was associated with product quality complaint.  The action taken with COVID-19 vaccine AD26.COV2.s, and elasomeran was not applicable and action taken with Paxlovid was treatment discontinued.  It was unknown whether the patient was taking any other medications or products within 2 weeks of starting COVID-19 treatment.  Company comment.  This spontaneous case concerns patient with no relevant medical history reported, who experienced the unexpected serious (medically significant) AESI of COVID-19, on an unknown date after receiving a dose of mRNA-1273 vaccine, considered as third dose of his COVID  19 immunization schedule; the patient previously received a dose of Janssen COVID  19 (interchange of vaccine products was considered) and a dose of mRNA - 1273. It was reported that the patient was treated with Nirmatrelvir, Ritonavir (Paxlovid) for five days. No further information was provided for medical reviewing. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 29-Jun-2022: Follow-up included medical history, suspect, co suspect vaccine, treatment drug and event seriousness criteria was added. Event vaccination failure was deleted. I narrative supplement updated.; Sender's Comments: This spontaneous case concerns patient with no relevant medical history reported, who experienced the unexpected serious (medically significant) AESI of COVID-19, on an unknown date after receiving a dose of mRNA-1273 vaccine, considered as third dose of his COVID  19 immunization schedule; the patient previously received a dose of Janssen COVID  19 (interchange of vaccine products was considered) and a dose of mRNA - 1273. It was reported that the patient was treated with Nirmatrelvir, Ritonavir (Paxlovid) for five days. No further information was provided for medical reviewing. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.